Literature DB >> 23787440

Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage.

Leonardo Boiocchi1, Susan Mathew, Umberto Gianelli, Alessandra Iurlo, Tommaso Radice, Sharon Barouk-Fox, Daniel M Knowles, Attilio Orazi.   

Abstract

Polycythemia vera and primary myelofibrosis share a propensity to progress toward a myelofibrotic late stage with overlapping clinical characteristics. Bone marrow features potentially useful for distinguishing the two entities have not been thoroughly investigated and, currently, clinical history is used for purposes of disease classification. This study describes in detail the morphologic features of 23 cases of post-polycythemic myelofibrosis and 15 cases of primary myelofibrosis with a similar degree of fibrosis, from two large medical centers. Cytogenetic results were available in 19 post-polycythemic myelofibrosis and in 13 primary myelofibrosis cases. JAK2 status and follow-up information was available in all cases. Cellularity was increased in both groups, but more so in post-polycythemic myelofibrosis than in primary myelofibrosis. In post-polycythemic myelofibrosis, most megakaryocytes retained polycythemia vera-like features including normally folded and/or hyperlobulated nuclei devoid of severe maturation defects; only in a few cases were rare tight clusters present. In primary myelofibrosis cases, megakaryocytes showed pronounced anomalies, including increased nuclear:cytoplasmic ratio, abnormal clumping of chromatin and frequent tight clustering. No differences in blast number (<1%) or in the myeloid:erythroid ratio were observed. Post-polycythemic myelofibrosis showed a higher degree of karyotypic alterations and higher percentage of cases with complex karyotype and/or two or more clones. Chromosome 1 defects were common in post-polycythemic myelofibrosis, whereas isolated del(20q) was the most common alteration in primary myelofibrosis. No survival differences were noted between the two groups. Post-polycythemic myelofibrosis cases retain a distinct megakaryocytic morphology that represents a useful clue for differential diagnosis. In addition, they more often display a complex karyotype than do primary myelofibrosis cases. These results suggest that myelofibrosis in polycythemia vera represents a form of progression characterized by profound genetic damage whereas in primary myelofibrosis it is an intrinsic part of the phenotypic manifestation of the disease, not necessarily associated with adverse cytogenetics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23787440     DOI: 10.1038/modpathol.2013.109

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

Review 1.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 2.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

3.  Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.

Authors:  Krisstina Gowin; Maria Coakley; Heidi Kosiorek; Ruben Mesa
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

4.  Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis.

Authors:  K Gowin; S Verstovsek; N Daver; N Pemmaraju; R Valdez; H Kosiorek; A Dueck; R Mesa
Journal:  Leuk Res       Date:  2015-04-17       Impact factor: 3.156

Review 5.  How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.

Authors:  Andreas Reiter; Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

6.  Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

Authors:  Lucia Masarova; Prithviraj Bose; Naval Daver; Naveen Pemmaraju; Kate J Newberry; Taghi Manshouri; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2017-06-02       Impact factor: 3.156

7.  Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications.

Authors:  Leonardo Boiocchi; Umberto Gianelli; Alessandra Iurlo; Falko Fend; Irina Bonzheim; Daniele Cattaneo; Daniel M Knowles; Attilio Orazi
Journal:  Mod Pathol       Date:  2015-09-04       Impact factor: 7.842

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.